A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local definitive therapy.
Lattouf
Jean-Baptiste
JB
Urologic Oncology Branch, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Arlen
Philip M
PM
Pinto
Peter A
PA
Gulley
James L
JL
D019496:Cancer Vaccines / Q000008:administration & dosage*; D017321:Clinical Trials, Phase I as Topic; D005240:Feasibility Studies; D005587:Fowlpox virus; D005822:Genetic Vectors; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic / Q000008:administration & dosage*; D014616:Vaccinia virus
D019496:Cancer Vaccines; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; C479602:rF-TRICOM vaccine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor